再鼎医药：2025年第一季度总收入1.06亿美元，同比增长22%

Core Insights - The company reported total revenue of $106 million for Q1 2025, representing a year-over-year increase of 22% [1] - Product revenue netted $106 million, showing a year-over-year growth of 21% [1] - Operating loss was $56.3 million, a decrease of 20% compared to the previous year, while adjusted operating loss was $37.1 million, down 25% year-over-year [1] - As of March 31, 2025, the company had cash reserves of $857 million [1] - The company projects full-year revenue guidance for 2025 to be between $560 million and $590 million [1]